Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | 3004298 | PO / MO |
The patient took second dose three days, third dose days and fourth dose seven days after first dose; The patient took second, third and fourth doses of Vivotif vaccine, which was in the fridge that didn't have power for roughly more than 24h; The patient took second, third and fourth doses of Vivotif vaccine, which was in the fridge that didn't have power for roughly more than 24h; The patient took second, third and fourth doses of Vivotif vaccine, which was in the fridge that didn't have power for roughly more than 24h; Case reference number US-BN-2025-000900 is a spontaneous case report initially received from a pharmacist via Communication (reference number: USBAV25-0979) on 01-May-2025 and concerns a *51-years-old* female patient. The patient's relevant medical history and concomitant medication not provided. On 28-Apr-2025, the patient took the first dose of Vivotif (batch number: 3004298) at dose of one capsule, orally for indication reported as travel typhoid fever prevention and co-suspect Vitamin D3 (brand name: unknown, batch number: unknown), the dose, route or site of administration were unknown, for unknown indication. On *29-Apr-2025*, the patient lost power, and the fridge didn't have power for roughly *more than 24h* hours between Tuesday night and Wednesday afternoon. As reported, the patient skipped Wednesday dose of Vivotif *(explicitly coded as 'product temperature excursion issue' and 'product storage error')* On 01-May-2025, on day three after the first dose, the patient took the second dose of Vivotif (batch number: 3004298) at dose of one capsules, orally (explicitly coded as 'inappropriate schedule of vaccine administered' and *'product administration error'*). On *03-May-2025, five days after first dose*, the patient took third dose of Vivotif (batch number: 3004298) at dose of one capsule, orally *(explicitly coded as 'inappropriate schedule of vaccine administered' and 'product administration error').* *On 05-May-2025, seven days after first dose*, the patient took fourth dose of Vivotif (batch number: *304298*) at dose of one capsule, orally *(explicitly coded as 'inappropriate schedule of vaccine administered'). * *As reported, no additional doses given outside of original four doses dispensed.* At the time of the follow-up report, it was not reported if the patient experienced any adverse events due to Vivotif vaccine. All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*). Follow up information received from a pharmacist on 13-May-2025: New information included updated suspect product details and additional event. Follow up information received from a pharmacist on 30-May-2025: New information included updated suspect product details and updated power date.; Reporter's Comments: A 51-year-old female patient took the first dose of Vivotif for travel typhoid fever prevention. Reportedly, the patient lost power, and the fridge didn't have power for roughly more than 24h hours, which is considered as product temperature excursion issue and product storage error. The patient took the second dose of Vivotif, as reported 3 days after the first dose, which is considered as inappropriate schedule of vaccine administered and product administration error. On the days 5 and 7 after the first dose, the patient took the third and the fourth dose of Vivotif, which is considered as inappropriate schedule of vaccine administered and product administration error. It was unknown if the patient experienced any adverse events due to Vivotif vaccine. Inappropriate schedule of product administration, product administration error, product temperature excursion issue and product storage error are considered as listed per company convention. The patient's relevant medical history and concomitant medication details were not provided. Inappropriate schedule of product administration, product administration error, product temperature excursion issue and product storage error are not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 51-year-old female patient took the first dose of Vivotif for travel typhoid fever prevention. Reportedly, the patient lost power, and the fridge didn't have power for roughly more than 24h hours, which is considered as product temperature excursion issue and product storage error. The patient took the second dose of Vivotif, as reported 3 days after the first dose, which is considered as inappropriate schedule of vaccine administered and product administration error. On the days 5 and 7 after the first dose, the patient took the third and the fourth dose of Vivotif, which is considered as inappropriate schedule of vaccine administered and product administration error. It was unknown if the patient experienced any adverse events due to Vivotif vaccine. Inappropriate schedule of product administration, product administration error, product temperature excursion issue and product storage error are considered as listed per company convention. The patient's relevant medical history and concomitant medication details were not provided. Inappropriate schedule of product administration, product administration error, product temperature excursion issue and product storage error are not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.
VITAMIN D3
Test Name: Temperature; Result Unstructured Data: 72ºF